BIOL

BIOLASE

BIOL

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about BIOL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% new	0% 0

Jun 24

BIOLASE, Inc. is a leader in dental laser technology, with a market cap of $1.5 million and approximately $6.4 million in cash and cash equivalents.
The company expects 2024 full-year net revenue to increase by 6% to 8%, reaching between $52 million and $54 million.
Insiders may soon buy shares at current "bargain basement prices" due to the company's valuable product and patents.

Generated by AI

Sentiment

Of the messages about BIOL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +31.37
Bearish	—	—	—	0% -31.37

Bullish· Jun 18

$BIOL has the potential to reach $0.30+ due to a similar setup as $NCEL.
The stock is expected to see increased momentum and a potential squeeze due to elevated shares rotation and short float.
$BIOL is a strong buy opportunity, with many people looking to solve part of their money issues and the stock showing strong momentum.

Bearish· Mar 22

$BIOL's price is likely to drop due to a high number of short sellers, with some anticipating a 10% drop by 10am tomorrow.
The stock's available shares are drying up, which may lead to a shortage and increased demand, potentially causing the price to surge.
$BIOL's price has been extremely oversold, making it a potential buying opportunity, but some investors are skeptical of the stock's long-term prospects.

Generated by AI

Topics

Of the messages about BIOL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	25%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	75%

Earnings· May 2

BIOLASE, Inc. (BIOL) reported earnings that beat expectations by $0.01.
However, revenue came in short of forecasts.
Earnings beat was modest, with the company missing on revenue.

Announcements· Mar 22

BIOLASE, Inc. reported better-than-expected fourth-quarter earnings results, with a revenue of $13.49 million and an EPS loss of $(1.76).
The company achieved record consumable sales, including the introduction of recurring revenue subscriptions, and increased adoption of its industry-leading laser systems.
BIOLASE's proprietary laser products incorporate approximately 241 active patents and 21 patent-pending technologies designed to provide biologically and clinically superior performance with less pain.

Technical Analysis· Jul 22

BIOLASE, Inc. ($BIOL) is showing a strong bounce off the trendline, with a potential next stop at $0.50 if volume is strong.
The stock's trendline support is near $0.42, and a bounce is expected, with some analysts predicting a double bottom and a potential move to the low $0.40s.
Technical indicators, including the CCI and RSI, are indicating a downtrend, with some analysts predicting a further decline to $0.38 or $0.39 before a potential bounce.

Generated by AI

Community

Of the messages about BIOL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	55.56%
Newcomers	—	—	—	44.44%

Regulars· Jun 18

BIOLASE, Inc. ($BIOL) is facing delisting from the Nasdaq after the Nasdaq Hearings Panel determined to delist the company's common stock.
The stock's float rotation has been observed, with a count of 1 and an elevated volatility level, and the short percentage has been at 6.5% in recent observations.
$BIOLASE's stock price is experiencing a significant drop, down -42.13% in the pre-market, following the announcement of its delisting from the Nasdaq.

Newcomers· Mar 22

The newcomer is focusing on BIOLASE, Inc.'s recent Q4 earnings report, highlighting better-than-expected EPS results.
The newcomer believes that BIOLASE, Inc.'s premarket trading could be a good time to start investing.
The newcomer is uncertain about the company's performance, stating that BIOLASE, Inc. "HASN’T ANYTHING" to suggest a good investment opportunity.

Generated by AI

Also Discussed

Investors talking about BIOL also mention

#	Name	Attention
1	Inuvo Inc.INUV	0%0
2	GHSI - Guardion Health Sciences, Inc.	——
3	Castor Maritime Inc.CTRM	0%0
4	ZOM - Zomedica Corp.	——
5	China SXT Pharmaceuticals, Inc.SXTC	0%0
6	Destination XL Group Inc.DXLG	0%new
7	Tonix Pharmaceuticals Holding CorpTNXP	0.01%-0.18
8	Seanergy Maritime Holdings Corp.SHIP	0%0
9	Grace Therapeutics Inc.ACST	0%0
10	AEZS - Aeterna Zentaris Inc.	——

BIOLASE, Inc.

Location

Social

What share of all stock conversation is about BIOL?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% new	0% 0

Jun 24

BIOLASE, Inc. is a leader in dental laser technology, with a market cap of $1.5 million and approximately $6.4 million in cash and cash equivalents.
The company expects 2024 full-year net revenue to increase by 6% to 8%, reaching between $52 million and $54 million.
Insiders may soon buy shares at current "bargain basement prices" due to the company's valuable product and patents.

Generated by AI

Sentiment

Of the messages about BIOL that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	100% +31.37
Bearish	—	—	—	0% -31.37

Bullish· Jun 18

$BIOL has the potential to reach $0.30+ due to a similar setup as $NCEL.
The stock is expected to see increased momentum and a potential squeeze due to elevated shares rotation and short float.
$BIOL is a strong buy opportunity, with many people looking to solve part of their money issues and the stock showing strong momentum.

Bearish· Mar 22

$BIOL's price is likely to drop due to a high number of short sellers, with some anticipating a 10% drop by 10am tomorrow.
The stock's available shares are drying up, which may lead to a shortage and increased demand, potentially causing the price to surge.
$BIOL's price has been extremely oversold, making it a potential buying opportunity, but some investors are skeptical of the stock's long-term prospects.

Generated by AI

Topics

Of the messages about BIOL that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	25%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	75%

Earnings· May 2

BIOLASE, Inc. (BIOL) reported earnings that beat expectations by $0.01.
However, revenue came in short of forecasts.
Earnings beat was modest, with the company missing on revenue.

Announcements· Mar 22

BIOLASE, Inc. reported better-than-expected fourth-quarter earnings results, with a revenue of $13.49 million and an EPS loss of $(1.76).
The company achieved record consumable sales, including the introduction of recurring revenue subscriptions, and increased adoption of its industry-leading laser systems.
BIOLASE's proprietary laser products incorporate approximately 241 active patents and 21 patent-pending technologies designed to provide biologically and clinically superior performance with less pain.

Technical Analysis· Jul 22

BIOLASE, Inc. ($BIOL) is showing a strong bounce off the trendline, with a potential next stop at $0.50 if volume is strong.
The stock's trendline support is near $0.42, and a bounce is expected, with some analysts predicting a double bottom and a potential move to the low $0.40s.
Technical indicators, including the CCI and RSI, are indicating a downtrend, with some analysts predicting a further decline to $0.38 or $0.39 before a potential bounce.

Generated by AI

Community

Of the messages about BIOL, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	55.56%
Newcomers	—	—	—	44.44%

Regulars· Jun 18

BIOLASE, Inc. ($BIOL) is facing delisting from the Nasdaq after the Nasdaq Hearings Panel determined to delist the company's common stock.
The stock's float rotation has been observed, with a count of 1 and an elevated volatility level, and the short percentage has been at 6.5% in recent observations.
$BIOLASE's stock price is experiencing a significant drop, down -42.13% in the pre-market, following the announcement of its delisting from the Nasdaq.

Newcomers· Mar 22

The newcomer is focusing on BIOLASE, Inc.'s recent Q4 earnings report, highlighting better-than-expected EPS results.
The newcomer believes that BIOLASE, Inc.'s premarket trading could be a good time to start investing.
The newcomer is uncertain about the company's performance, stating that BIOLASE, Inc. "HASN’T ANYTHING" to suggest a good investment opportunity.

Generated by AI

BIOLASE

Social

Jun 24

Sentiment

Bullish· Jun 18

Bearish· Mar 22

Topics

Earnings· May 2

Announcements· Mar 22

Technical Analysis· Jul 22

Community

Regulars· Jun 18

Newcomers· Mar 22

Also Discussed

BIOLASE, Inc.

Company Information

Location

Also Discussed

Social

Jun 24

Sentiment

Bullish· Jun 18

Bearish· Mar 22

Topics

Earnings· May 2

Announcements· Mar 22

Technical Analysis· Jul 22

Community

Regulars· Jun 18

Newcomers· Mar 22